Integra Therapeutics, member of CATALONIA.HEALTH, will receive a grant of 2.5 million euros and equity investment of up to 8 million euros from the European Commission via the European Innovation Council (EIC) Accelerator program, which combines grants and capital for emerging European DeepTech companies. It is one of the 68 companies selected from a total of 969 companies that opted for the fund.  

Integra Therapeutics will earmark the initial €2.5 million for pre-marketing activities of its FiCAT platform for T cell and hematopoietic stem cell (HSC) engineering to develop cell therapies in rare diseases, autoimmune diseases, and oncology. In parallel, the FiCAT concept test will be carried out in a gene therapy to treat a serious pediatric hepatic disease. It will also promote the expansion of the FiCAT platform to extrahepatic indications.  

“The funding from the EIC Accelerator is a huge impetus for Integra Therapeutics and our FiCAT gene writing platform because it will lead to the development of the first therapeutic product in the preclinical and clinical regulatory phases for a disease with a huge medical need in children that is currently unmet,” explains Avencia Sánchez-Mejías, CEO and co-founder of Integra Therapeutics. In addition, she added, “I am pleased to see that 21% of the companies chosen are led by women, which is an improvement over the previous call, although there is still room for improvement in the gender gap in leadership positions in our sector”. 

More information 

Related news: 

• Integra Therapeutics to present ex vivo and in vivo data for its FiCAT gene-writing platform (14 September 2023) 

• Integra Therapeutics closes a new investment of €1.5-million with the addition of Columbus Venture Partners to seed round (30 March 2022)